Table 1.

Patient demographic/clinical characteristics and indications for therapy

Variable	Value for posaconazole patients (n = 86)
Demographics
Median age [yr (range)]	51 (18–79)
No. of males/females	50/36
Median wt [kg (range)a]	71 (38–122)
No. with indication for therapyb:
Antifungal prophylaxis	72
Proven IFI	6
Probable IFI	3
Possible IFI	3
Empirical therapy	2
No. with underlying condition:
Acute myeloid leukemia	38
Acute lymphoblastic leukemia	11
Non-Hodgkin's lymphoma	8
Myelodysplastic syndrome	6
Multiple myeloma	4
Diabetes mellitus type 2	4
Chronic lymphocytic leukemia	3
Otherc	12

^aWeight was available for 85/86 patients.

^bPatients receiving posaconazole for treatment of a fungal infection defined according to the 2008 EORTC/MSG guidelines (8).

^cMyelofibrosis (2 patients), Hodgkin's lymphoma (1 patient), acute biphenotypic leukemia (1 patient), gray-zone lymphoma (1 patient), T-polylymphocytic leukemia (1 patient), chronic myeloid leukemia (1 patient), aplastic anemia (1 patient), HIV positivity (1 patient), rheumatoid arthritis (1 patient), Crohn's disease (1 patient), and none (histoplasma) (1 patient).